Sarah Acaster

Sarah Acaster

Director

Biography

Sarah has over 15 years’ experience in outcomes research, initially as an academic researcher, and subsequently in a research consultancy role. She led COA teams in the US and Europe working as a Director for ICON Plc and Oxford Outcomes. She established her own consultancy in 2013 in order to reconnect to the research front line and offer bespoke consulting; happily, this led to collaboration with Andrew and the creation of Acaster Lloyd Consulting in 2016.

Sarah’s research and consultancy interests span the entire lifecycle of drug development, from concept scoping to licensing, reimbursement and beyond. As well as her experience in the development, selection and use of COAs, she has particular expertise in utility and preference-based studies, including conjoint analysis, secondary analysis of COA data and more specifically the interpretation of COA data. She is also interested in COA strategy and has provided consultancy to clients in relation to their FDA, EMA and HTA regulatory strategies.

Sarah is an active member of ISPOR and ISOQOL and is regularly involved in teaching workshops related to patient-reported outcome (PRO) development, COA interpretation and utility studies. She is also a co-editor of Value in Health.

Andrew Lloyd

Andrew Lloyd

Director

Biography

Andrew’s background is in patient-reported outcome research and he has considerable experience in patient preferences/utilities. He has held senior positions at ICON plc, Oxford Outcomes and United BioSource Corporation in London. He also held research posts at several universities within the UK and supervised several students at masters and doctoral level. Each year he teaches on a residential course at the University of York on health outcomes measurement and holds a research affiliation with University of Bath.

Andrew’s research is focused on developing and testing assessments of health-related quality of life with a particular focus on utility measurement. He has undertaken work to support HTA and regulatory submissions in a broad range of therapeutic areas including oncology, rare diseases, autoimmune disease as well as work on medical devices. Apart from that, he is an active member of ISPOR, where he teaches on their short course programs in the EU and US. He is also a co-editor of Value in Health, sits on the international advisory board for the Journal Quality of Life Research and is on the Executive Committee of the EuroQol Group. He has chaired many international advisory boards designed to explore reimbursement and market access issues.